Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Tissue Engineering & Bioprinting: Research to Commercialization

Keith Murphy's Biography

Keith Murphy, CEO, Organovo

Mr. Murphy has more than 20 years of experience in biotechnology, including serving in Product Strategy and Director of Process Development roles at Amgen. He is a co-founder of Organovo and has been responsible for all company operations since 2007. His ten years at Amgen included four years as Global Operations Leader for the largest development program in Amgen’s history, Phase 3 osteoporosis/bone cancer drug denosumab. At Amgen, he also worked to develop several other novel formulation and device products. Prior to Amgen, he played a central role at Alkermes, Inc. on the development team for their first approved product, Nutropin (hGH) Depot. He holds a B.S. in chemical engineering from the Massachusetts Institute of Technology and is an alumnus of the UCLA Anderson School of Management.

Keith Murphy Image

Commercial Opportunities for Bioprinting

Monday, 9 February 2015 at 17:30

Add to Calendar ▼2015-02-09 09:45:002015-02-09 10:45:00Europe/LondonCommercial Opportunities for BioprintingTissue Engineering and Bioprinting: Research to Commercialization in Boston, USABoston,

Bioprinting is opening up new technical solutions for many disciplines.  Academic and industrial scientists are working to expand the technologies and the uses of bioprinting. The commercial opportunities are broad, and are still being explored. There are many hurdles to commercial maturity, but the key to success is the technologies in the field, which are already in fast-paced development and will ultimately lead the way.

Add to Calendar ▼2015-02-09 00:00:002015-02-10 00:00:00Europe/LondonTissue Engineering and Bioprinting: Research to CommercializationTissue Engineering and Bioprinting: Research to Commercialization in Boston, USABoston,